肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究进展  

Clinical progress of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome

作　　者：郭丰年 赵源 何军 陆伟根 GUO Fengnian;ZHAO Yuan;HE Jun;LU Weigen(China State Institute of Pharmaceutical Industry,Shanghai 201203,China)

机构地区：[1]中国医药工业研究总院,上海201203

出　　处：《世界临床药物》2024年第2期204-208,共5页World Clinical Drug

摘　　要：新生儿呼吸窘迫综合征(neonatal respiratory distress syndrome,NRDS)是新生儿因肺组织发育不成熟导致肺表面活性物质(pulmonary surfactant,PS)缺乏,进而产生进行性呼吸困难、呼吸衰竭(respiratory failure)等症状的新生儿呼吸系统疾病。临床上普遍使用PS替代疗法治疗NRDS。随着相关研究的深入和临床用药知识的不断丰富,越来越多PS的临床优化给药方案被报道。该文综述NRDS治疗中PS的临床应用情况,对药物种类、给药方式、给药时机、给药剂量及给药装置等最新研究结果进行汇总,探讨PS未来用于治疗其他呼吸系统疾病的可能性,为提高PS的临床应用水平提供依据。Neonatal respiratory distress syndrome(NRDS)is a neonatal respiratory disease caused by insufficient secretion of pulmonary surfactant(PS)due to immature lung tissue,it can cause progressive dyspnea,respiratory failure and other lung symptoms.PS replacement therapy is widely used in clinical practice to treat NRDS.With the deepening of related studies and the continuous enrichment of clinical medication knowledge,more and more clinical optimal drug delivery routes of PS have been reported.This article reviewed the clinical application of PS in NRDS and summarized the latest research results of new PS,administration route,administration timing,administration dose,and administration device,and also discussed the possibility application of PS in other respiratory diseases,to provide the reference for improving the level of clinical application of PS.

关 键 词：新生儿呼吸窘迫综合征 肺表面活性剂 儿童用药 无创给药技术 

分 类 号：R985[医药卫生—药品] R722.12[医药卫生—药学]